Higel Fabian, Seidl Andreas, Sörgel Fritz, Friess Wolfgang
Sandoz Biopharmaceuticals, HEXAL AG, Oberhaching, Germany.
Sandoz Biopharmaceuticals, HEXAL AG, Oberhaching, Germany.
Eur J Pharm Biopharm. 2016 Mar;100:94-100. doi: 10.1016/j.ejpb.2016.01.005. Epub 2016 Jan 13.
Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.
单克隆抗体和Fc融合蛋白药物是由众多不同蛋白质变体和修饰组成的复杂异质混合物。N-糖基化作为最复杂的翻译后修饰之一,影响抗体Fc部分的结构特征,从而可能调节效应功能和药代动力学。关于N-糖基化与药代动力学之间关系的多项研究已经发表。然而,这种结构-功能关系尚未完全明确。在本综述中,重点回顾了单克隆抗体和Fc融合蛋白N-糖基化的潜在变化及其对药代动力学的可能影响,并描述了对潜在机制的当前认识。